PMID- 35207711
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220301
IS  - 2075-4426 (Print)
IS  - 2075-4426 (Electronic)
IS  - 2075-4426 (Linking)
VI  - 12
IP  - 2
DP  - 2022 Feb 6
TI  - Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor 
      Agonists in Patients with Diabetic Kidney Disease.
LID - 10.3390/jpm12020223 [doi]
LID - 223
AB  - For almost two decades, the management of patients with type 2 diabetes mellitus 
      (T2DM) and chronic kidney disease (CKD) was based on the optimal glycemic and 
      blood pressure control as well as on the adequate blockade of the 
      renin-angiotensin-system. Over the past few years, sodium-glucose co-transporter 
      2 (SGLT-2) inhibitors and glucagone-like peptide 1 receptor agonists (GLP1-RAs) 
      were added to our therapeutic armarhatum, offering promise for more effective 
      mitigation of the substantial residual cardiorenal risk of these patients. Large 
      randomized controlled trials (RCTs) designed to demonstrate the cardiovascular 
      safety of SGLT-2 inhibitors and GLP1-RAs showed that these novel anti-diabetic 
      medications improve cardiovascular outcomes in patients with T2DM. RCTs conducted 
      specifically in CKD patients with or without T2DM demonstrated that SGLT-2 
      inhibitors were also effective in retarding the progression of kidney injury to 
      end-stage kidney disease. The kidney protective effects of GLP1-RA are not yet 
      proven, but RCTs are currently ongoing to investigate this crucial research 
      question. In this article, we review the available clinical-trial evidence 
      supporting the use of SGLT-2 inhibitors and GLP1-RAs for cardiorenal protection 
      in patients with T2DM and CKD. We provide clinical practice recommendations for a 
      personalized approach in the use of these novel therapies, according to the 
      severity of CKD and the presence of other cardiometabolic risk factors.
FAU - Georgianos, Panagiotis I
AU  - Georgianos PI
AD  - Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA 
      Hospital, Aristotle University of Thessaloniki, GR54636 Thessaloniki, Greece.
FAU - Vaios, Vasilios
AU  - Vaios V
AD  - Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA 
      Hospital, Aristotle University of Thessaloniki, GR54636 Thessaloniki, Greece.
FAU - Roumeliotis, Stefanos
AU  - Roumeliotis S
AUID- ORCID: 0000-0002-9423-649X
AD  - Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA 
      Hospital, Aristotle University of Thessaloniki, GR54636 Thessaloniki, Greece.
FAU - Leivaditis, Konstantinos
AU  - Leivaditis K
AD  - Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA 
      Hospital, Aristotle University of Thessaloniki, GR54636 Thessaloniki, Greece.
FAU - Eleftheriadis, Theodoros
AU  - Eleftheriadis T
AUID- ORCID: 0000-0001-9302-1633
AD  - Department of Nephrology, School of Medicine, University of Thessaly, GR4110 
      Larissa, Greece.
FAU - Liakopoulos, Vassilios
AU  - Liakopoulos V
AUID- ORCID: 0000-0002-7564-2724
AD  - Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA 
      Hospital, Aristotle University of Thessaloniki, GR54636 Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220206
PL  - Switzerland
TA  - J Pers Med
JT  - Journal of personalized medicine
JID - 101602269
PMC - PMC8874759
OTO - NOTNLM
OT  - GLP1-RA
OT  - SGLT-2 inhibitors
OT  - cardiorenal protection
OT  - diabetic kidney disease
OT  - randomized controlled trials
COIS- The authors declare no conflict of interest.
EDAT- 2022/02/26 06:00
MHDA- 2022/02/26 06:01
PMCR- 2022/02/06
CRDT- 2022/02/25 01:12
PHST- 2022/01/09 00:00 [received]
PHST- 2022/01/30 00:00 [revised]
PHST- 2022/02/03 00:00 [accepted]
PHST- 2022/02/25 01:12 [entrez]
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/02/26 06:01 [medline]
PHST- 2022/02/06 00:00 [pmc-release]
AID - jpm12020223 [pii]
AID - jpm-12-00223 [pii]
AID - 10.3390/jpm12020223 [doi]
PST - epublish
SO  - J Pers Med. 2022 Feb 6;12(2):223. doi: 10.3390/jpm12020223.